The past few months at T3 Labs have been immensely productive. Along with our preclinical sponsors we continue to produce ground-breaking data. Our sponsors continue to receive regulatory approvals maximizing their investment in preclinical. And our medical device training program continues to ensure physicians and surgeons develop the skills required to fully realize the value of the medtech innovations generated through the device development process including preclinical research, in which we specialize.
As 2015 draws to a close, we share here a few highlights and a few things we’re looking forward to in 2016. Come along!
T3 Labs 2015 Preclinical Highlights
Alizee Pathology generated the “first preclinical testing documentation that a progressive regenerative response occurs as early as 7 days after renal denervation, resulting in a poorly organized neuromatous regeneration. This finding is of paramount importance to further establish the potential functional significance of regeneration after renal denervation.”
Surefire Medical achieved 510k regulatory approval for Surefire Precision in record time for the company. Surefire followed this up a few months later with the announcement of a $15 million Series C funding round for the global launch of its direct-to-tumor delivery device employed in minimally invasive chemoembolization and radioembolization procedures.
Our Executive Director Andrew Stevenson and Advisory Board Chair Tiffany Wilson shared their insights on what it takes to build a leading medtech ecosystem with CW Hall and Health Connect South Radio.
Connect with T3 Labs in 2016
In 2016, the T3 team will be engaging with leaders in medtech innovation across the country at events including the Society of Thoracic Surgeons 52nd Annual Meeting, Cardiovascular Research Technologies 2016, the American Association of Orthpaedic Surgeons and the Pediatric Orthopaedic Society of North America and more. Keep up with the T3 team’s travels on our events page and follow us on our active LinkedIn and Twitter profiles!
If you are evaluating a medical device, drug or biologic readiness for preclinical or if you need the finest facilities and resources available for medical device training, contact email@example.com or call 404-251-0600.